Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells

Lionel Franz Poulin, Mariolina Salio, Emmanuel Griessinger, Fernando Anjos-Afonso, Ligia Craciun, Ji-Li Chen, Anna M Keller, Olivier Joffre, Santiago Zelenay, Emma Nye, Alain Le Moine, Florence Faure, Vincent Donckier, David Sancho, Vincenzo Cerundolo, Dominique Bonnet, Caetano Reis e Sousa, Lionel Franz Poulin, Mariolina Salio, Emmanuel Griessinger, Fernando Anjos-Afonso, Ligia Craciun, Ji-Li Chen, Anna M Keller, Olivier Joffre, Santiago Zelenay, Emma Nye, Alain Le Moine, Florence Faure, Vincent Donckier, David Sancho, Vincenzo Cerundolo, Dominique Bonnet, Caetano Reis e Sousa

Abstract

In mouse, a subset of dendritic cells (DCs) known as CD8alpha+ DCs has emerged as an important player in the regulation of T cell responses and a promising target in vaccination strategies. However, translation into clinical protocols has been hampered by the failure to identify CD8alpha+ DCs in humans. Here, we characterize a population of human DCs that expresses DNGR-1 (CLEC9A) and high levels of BDCA3 and resembles mouse CD8alpha+ DCs in phenotype and function. We describe the presence of such cells in the spleens of humans and humanized mice and report on a protocol to generate them in vitro. Like mouse CD8alpha+ DCs, human DNGR-1+ BDCA3hi DCs express Necl2, CD207, BATF3, IRF8, and TLR3, but not CD11b, IRF4, TLR7, or (unlike CD8alpha+ DCs) TLR9. DNGR-1+ BDCA3hi DCs respond to poly I:C and agonists of TLR8, but not of TLR7, and produce interleukin (IL)-12 when given innate and T cell-derived signals. Notably, DNGR-1+ BDCA3+ DCs from in vitro cultures efficiently internalize material from dead cells and can cross-present exogenous antigens to CD8+ T cells upon treatment with poly I:C. The characterization of human DNGR-1+ BDCA3hi DCs and the ability to grow them in vitro opens the door for exploiting this subset in immunotherapy.

Figures

Figure 1.
Figure 1.
DNGR-1+ BDCA3hi DCs are found in the spleens of humans. (A) Flow cytometry analysis of human spleen cell suspensions from cadaveric donors. Live HLA-DR+ Lin− cells were gated as shown (top left) and analyzed for expression of BDCA3 versus DNGR-1 (top right). Three populations were defined (gate I: BDCA3hi, DNGR-1+; gate II: BDCA3int, DNGR-1−; gate III: BDCA3−, DNGR-1−) and analyzed for the expression of CD11c versus BDCA1, BDCA2 or CD11b (bottom). Numbers indicate percentage of cells in each of the indicated gates or quadrants. Arrows show gating strategy. (B) Normalized expression of DNGR-1, Necl2, and IRF8 mRNA on sorted HLA-DR+ Lin− BDCA2− BDCA1− DCs, from human spleen, expressing high (BDCA3hi), intermediate (BDCA3int), or low levels of BDCA3 (BDCA3−). ND, not detectable. Data in A and B are representative of at least three cadaveric donors. Additional data analysis is shown in Fig. S1 and a summary of DC population frequency across three donors is presented in Table S1.
Figure 2.
Figure 2.
DNGR-1+ BDCA3hi DCs are found in the spleens of humanized mice. HLA-DR+ Lin− live spleen cells from humanized mice (NOD/SCID/γc) were analyzed as in Fig. 1 for the expression of BDCA3 versus BDCA2 (top right), BDCA3 versus DNGR-1 (middle left), and BDCA2 versus DNGR-1 (middle right). The scatter profile of BDCA3+ and BDCA2+ cells is also shown (bottom). Numbers indicate percentage of cells in each of the indicated gates or quadrants. Arrows show gating strategy. Data are representative of multiple mice from three independent cohorts of mice engrafted with human HSCs/HPCs.
Figure 3.
Figure 3.
Phenotype of in vitro–generated DNGR-1+ BDCA3+ CBDCs. CBDCs were generated as described in the Materials and methods. Live cells were analyzed for the expression of BDCA3 versus DNGR-1 (A), CD1a versus DNGR-1 (B, left), and CD1a versus HLA-DR (B, middle). Gated CD1a+ HLA-DR+ cells were analyzed for the expression of BDCA3 versus DNGR-1 (B, right). Numbers indicate percentage of cells in each of the indicated gates or quadrants. Arrows show gating strategy. (C) CBDCs were treated with or without poly I:C (10 µg/ml) overnight and subsequently sorted into live HLA-DR+ Lin− DNGR-1+ cells. Cytospins were prepared and morphology was assessed by hematoxylin and eosin staining. Bar, 5 µm. (D) Live DNGR-1+ DCs were analyzed for the expression (red) of CD11c, BDCA1, CD8α, BDCA2, CD83, CD86, CD40, CD103, CD45RO, CD123, CCR7, EpCam, and CD11b. Isotype-matched control mAb staining is shown in the blue histograms. Data in A–D are representative of multiple BDC cultures with two independent pools of CB-derived HSCs/HPCs.
Figure 4.
Figure 4.
DNGR-1+ BDCA3+ DCs display a gene expression profile characteristic of mouse CD8α+ DCs. Normalized expression of DNGR-1, Necl2, CD207, BATF3, IRF8, IRF4, TLR7, TLR9, DAP12, TLR8, and TLR3 mRNA in BDCA3+ DNGR-1+ DCs (DNGR-1+) purified either from CBDCs or from pooled spleens of two to five humanized mice (hu mice). Expression was compared with that of BDCA2+ pDCs purified from the same humanized mouse spleens. Data are representative of two independent experiments. ND, not detectable.
Figure 5.
Figure 5.
DNGR-1+ BDCA3+ DCs respond to poly I:C and to TLR8, but not TLR7 agonists. (A) Purified DNGR-1+ BDCA3+ DCs from CBDCs (DNGR-1+ CBDCs) or from humanized mice (DNGR-1+ hu mice), or BDCA2+ pDCs from the same humanized mice (BDCA2+ hu mice), were cultured with poly I:C (10 µg/ml), imiquimod (10 µg/ml), or medium alone. After overnight incubation, culture supernatant was tested for TNF and IL-6 content. (B) DNGR-1+ CBDCs as in (A) were cultured with resiquimod (10 µg/ml), poly U (10 µg/ml) or medium alone. Supernatant was tested for IL-6 after overnight culture. (C) DNGR-1+ BDCA3+ DCs purified from CBDCs (DNGR-1+ CBDCs) or human spleen (DNGR-1+ hu spleen) were cultured with a mix of TLR agonists and cytokines with or without antigen-specific T cells and antigen, as described in the Materials and methods. Supernatant was tested for IL-12 p70 after overnight culture. Data in A–C are representative of at least two independent experiments with independent sources of cells. ND, not detectable.
Figure 6.
Figure 6.
DNGR-1+ BDCA3+ DCs internalize dead cell debris and cross-present exogenous antigens. (A) CBDCs or Mo-DCs were incubated with labeled dead melanoma cells at the indicated ratios, as described in the Materials and methods. Uptake of dead cell material by DNGR-1+ DCs or Mo-DCs was quantified by flow cytometry (left) and confirmed by confocal microscopy (right; blue shows dead cell material). Data are mean ± SEM of three biological replicates from one experiment representative of two independent experiments. Bar, 5 µm. (B) 104 purified BDCA3+ DNGR-1+ CBDCs or Mo-DCs, as indicated, were pulsed for 2–3 h with or without 1 µM MelanA/MART-1 long peptide as antigen source for cross-presentation or the same concentration of short peptide as a processing-independent control, in the presence or absence of poly I:C. Cells were subsequently washed twice and co-cultured with a MelanA-specific CD8+ T cell clone at a 5:1 T:DCs ratio. IFN-γ accumulation in culture supernatants was assessed after 40 h. Data are the mean value of duplicate wells ± range and are representative of two independent experiments.

References

    1. Albert M.L., Sauter B., Bhardwaj N. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:86–89 10.1038/32183
    1. Ban Y.-L., Kong B.-H., Qu X., Yang Q.-F., Ma Y.-Y. 2008. BDCA-1+, BDCA-2+ and BDCA-3+ dendritic cells in early human pregnancy decidua. Clin. Exp. Immunol. 151:399–406
    1. Bedoui S., Whitney P.G., Waithman J., Eidsmo L., Wakim L., Caminschi I., Allan R.S., Wojtasiak M., Shortman K., Carbone F.R., et al. 2009. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat. Immunol. 10:488–495 10.1038/ni.1724
    1. Bursch L.S., Wang L., Igyarto B., Kissenpfennig A., Malissen B., Kaplan D.H., Hogquist K.A. 2007. Identification of a novel population of Langerin+ dendritic cells. J. Exp. Med. 204:3147–3156 10.1084/jem.20071966
    1. Caminschi I., Proietto A.I., Ahmet F., Kitsoulis S., Shin Teh J., Lo J.C., Rizzitelli A., Wu L., Vremec D., van Dommelen S.L., et al. 2008. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood. 112:3264–3273 10.1182/blood-2008-05-155176
    1. Chen J.L., Dunbar P.R., Gileadi U., Jäger E., Gnjatic S., Nagata Y., Stockert E., Panicali D.L., Chen Y.T., Knuth A., et al. 2000. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J. Immunol. 165:948–955
    1. Chen J.L., Stewart-Jones G., Bossi G., Lissin N.M., Wooldridge L., Choi E.M., Held G., Dunbar P.R., Esnouf R.M., Sami M., et al. 2005. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 201:1243–1255 10.1084/jem.20042323
    1. Cravens P.D., Melkus M.W., Padgett-Thomas A., Islas-Ohlmayer M., Del P Martin M., Garcia J.V. 2005. Development and activation of human dendritic cells in vivo in a xenograft model of human hematopoiesis. Stem Cells. 23:264–278 10.1634/stemcells.2004-0116
    1. Daubenberger C.A. 2007. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr. Opin. Mol. Ther. 9:45–52
    1. Delamarre L., Holcombe H., Mellman I. 2003. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J. Exp. Med. 198:111–122 10.1084/jem.20021542
    1. Demedts I.K., Brusselle G.G., Vermaelen K.Y., Pauwels R.A. 2005. Identification and characterization of human pulmonary dendritic cells. Am. J. Respir. Cell Mol. Biol. 32:177–184 10.1165/rcmb.2004-0279OC
    1. Diebold S.S., Kaisho T., Hemmi H., Akira S., Reis e Sousa C. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 303:1529–1531 10.1126/science.1093616
    1. Dudziak D., Kamphorst A.O., Heidkamp G.F., Buchholz V.R., Trumpfheller C., Yamazaki S., Cheong C., Liu K., Lee H.W., Park C.G., et al. 2007. Differential antigen processing by dendritic cell subsets in vivo. Science. 315:107–111 10.1126/science.1136080
    1. Dzionek A., Fuchs A., Schmidt P., Cremer S., Zysk M., Miltenyi S., Buck D.W., Schmitz J. 2000. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165:6037–6046
    1. Edelson B.T., Kc W., Juang R., Kohyama M., Benoit L.A., Klekotka P.A., Moon C., Albring J.C., Ise W., Michael D.G., et al. 2010. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells. J. Exp. Med. 207:823–836 10.1084/jem.20091627
    1. Edwards A.D., Diebold S.S., Slack E.M., Tomizawa H., Hemmi H., Kaisho T., Akira S., Reis e Sousa C. 2003. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 α+ DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33:827–833 10.1002/eji.200323797
    1. Faure F., Mantegazza A., Sadaka C., Sedlik C., Jotereau F., Amigorena S. 2009. Long-lasting cross-presentation of tumor antigen in human DC. Eur. J. Immunol. 39:380–390 10.1002/eji.200838669
    1. Fiore N., Castellano G., Blasi A., Capobianco C., Loverre A., Montinaro V., Netti S., Torres D., Manno C., Grandaliano G., et al. 2008. Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Mol. Immunol. 45:259–265 10.1016/j.molimm.2007.04.029
    1. Galibert L., Diemer G.S., Liu Z., Johnson R.S., Smith J.L., Walzer T., Comeau M.R., Rauch C.T., Wolfson M.F., Sorensen R.A., et al. 2005. Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule. J. Biol. Chem. 280:21955–21964 10.1074/jbc.M502095200
    1. Gilliet M., Cao W., Liu Y.J. 2008. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8:594–606 10.1038/nri2358
    1. Ginhoux F., Liu K., Helft J., Bogunovic M., Greter M., Hashimoto D., Price J., Yin N., Bromberg J., Lira S.A., et al. 2009. The origin and development of nonlymphoid tissue CD103+ DCs. J. Exp. Med. 206:3115–3130 10.1084/jem.20091756
    1. Heath W.R., Carbone F.R. 2009. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat. Immunol. 10:1237–1244 10.1038/ni.1822
    1. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., Bauer S. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 303:1526–1529 10.1126/science.1093620
    1. Henri S., Poulin L.F., Tamoutounour S., Ardouin L., Guilliams M., de Bovis B., Devilard E., Viret C., Azukizawa H., Kissenpfennig A., Malissen B. 2010. CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J. Exp. Med. 207:189–206: S1–S6 10.1084/jem.20091964
    1. Hildner K., Edelson B.T., Purtha W.E., Diamond M., Matsushita H., Kohyama M., Calderon B., Schraml B.U., Unanue E.R., Diamond M.S., et al. 2008. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 322:1097–1100 10.1126/science.1164206
    1. Hochrein H., O’Keeffe M., Luft T., Vandenabeele S., Grumont R.J., Maraskovsky E., Shortman K. 2000. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J. Exp. Med. 192:823–833 10.1084/jem.192.6.823
    1. Huysamen C., Willment J.A., Dennehy K.M., Brown G.D. 2008. CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes. J. Biol. Chem. 283:16693–16701 10.1074/jbc.M709923200
    1. Inaba K., Swiggard W.J., Inaba M., Meltzer J., Mirza A., Sasagawa T., Nussenzweig M.C., Steinman R.M. 1995. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. I. Expression on dendritic cells and other subsets of mouse leukocytes. Cell. Immunol. 163:148–156 10.1006/cimm.1995.1109
    1. Inaba K., Turley S., Iyoda T., Yamaide F., Shimoyama S., Reis e Sousa C., Germain R.N., Mellman I., Steinman R.M. 2000. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J. Exp. Med. 191:927–936 10.1084/jem.191.6.927
    1. Iyoda T., Shimoyama S., Liu K., Omatsu Y., Akiyama Y., Maeda Y., Takahara K., Steinman R.M., Inaba K. 2002. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 195:1289–1302 10.1084/jem.20020161
    1. Joffre O.P., Sancho D., Zelenay S., Keller A.M., Reis e Sousa C. 2010. Efficient and versatile manipulation of the peripheral CD4(+) T cell compartment by antigen targeting to DNGR-1 / CLEC9A. Eur. J. Immunol. 40:1255–1265
    1. Klechevsky E., Morita R., Liu M., Cao Y., Coquery S., Thompson-Snipes L., Briere F., Chaussabel D., Zurawski G., Palucka A.K., et al. 2008. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity. 29:497–510 10.1016/j.immuni.2008.07.013
    1. Lindstedt M., Lundberg K., Borrebaeck C.A. 2005. Gene family clustering identifies functionally associated subsets of human in vivo blood and tonsillar dendritic cells. J. Immunol. 175:4839–4846
    1. Luber C.A., Cox J., Lauterbach H., Fancke B., Selbach M., Tschopp J., Akira S., Wiegand M., Hochrein H., O’Keeffe M., Mann M. 2010. Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity. 32:279–289 10.1016/j.immuni.2010.01.013
    1. MacDonald K.P., Munster D.J., Clark G.J., Dzionek A., Schmitz J., Hart D.N. 2002. Characterization of human blood dendritic cell subsets. Blood. 100:4512–4520 10.1182/blood-2001-11-0097
    1. Maraskovsky E., Brasel K., Teepe M., Roux E.R., Lyman S.D., Shortman K., McKenna H.J. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953–1962 10.1084/jem.184.5.1953
    1. McIlroy D., Troadec C., Grassi F., Samri A., Barrou B., Autran B., Debré P., Feuillard J., Hosmalin A. 2001. Investigation of human spleen dendritic cell phenotype and distribution reveals evidence of in vivo activation in a subset of organ donors. Blood. 97:3470–3477 10.1182/blood.V97.11.3470
    1. Merad M., Manz M.G. 2009. Dendritic cell homeostasis. Blood. 113:3418–3427 10.1182/blood-2008-12-180646
    1. Naik S.H. 2008. Demystifying the development of dendritic cell subtypes, a little. Immunol. Cell Biol. 86:439–452 10.1038/icb.2008.28
    1. Naik S.H., Proietto A.I., Wilson N.S., Dakic A., Schnorrer P., Fuchsberger M., Lahoud M.H., O’Keeffe M., Shao Q.X., Chen W.F., et al. 2005. Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J. Immunol. 174:6592–6597
    1. Narbutt J., Lesiak A., Sysa-Jedrzejowska A., Smolewski P., Robak T., Zalewska A. 2006. The number and distribution of blood dendritic cells in the epidermis and dermis of healthy human subjects. Folia Histochem. Cytobiol. 44:61–63
    1. Porcelli S., Morita C.T., Brenner M.B. 1992. CD1b restricts the response of human CD4-8- T lymphocytes to a microbial antigen. Nature. 360:593–597 10.1038/360593a0
    1. Robbins S.H., Walzer T., Dembélé D., Thibault C., Defays A., Bessou G., Xu H., Vivier E., Sellars M., Pierre P., et al. 2008. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol. 9:R17 10.1186/gb-2008-9-1-r17
    1. Salio M., Shepherd D., Dunbar P.R., Palmowski M., Murphy K., Wu L., Cerundolo V. 2001. Mature dendritic cells prime functionally superior melan-A-specific CD8+ lymphocytes as compared with nonprofessional APC. J. Immunol. 167:1188–1197
    1. Sallusto F., Cella M., Danieli C., Lanzavecchia A. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182:389–400 10.1084/jem.182.2.389
    1. Sancho D., Mourão-Sá D., Joffre O.P., Schulz O., Rogers N.C., Pennington D.J., Carlyle J.R., Reis e Sousa C. 2008. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest. 118:2098–2110 10.1172/JCI34584
    1. Schiavoni G., Mattei F., Sestili P., Borghi P., Venditti M., Morse H.C., III, Belardelli F., Gabriele L. 2002. ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8α+ dendritic cells. J. Exp. Med. 196:1415–1425 10.1084/jem.20021263
    1. Schulz O., Reis e Sousa C. 2002. Cross-presentation of cell-associated antigens by CD8α+ dendritic cells is attributable to their ability to internalize dead cells. Immunology. 107:183–189 10.1046/j.1365-2567.2002.01513.x
    1. Schulz O., Edwards A.D., Schito M., Aliberti J., Manickasingham S., Sher A., Reis e Sousa C. 2000. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity. 13:453–462 10.1016/S1074-7613(00)00045-5
    1. Shortman K., Heath W.R. 2010. The CD8+ dendritic cell subset. Immunol. Rev. 234:18–31 10.1111/j.0105-2896.2009.00870.x
    1. Steinman R.M. 2008. Dendritic cells in vivo: a key target for a new vaccine science. Immunity. 29:319–324 10.1016/j.immuni.2008.08.001
    1. Takahara K., Omatsu Y., Yashima Y., Maeda Y., Tanaka S., Iyoda T., Clausen B.E., Matsubara K., Letterio J., Steinman R.M., et al. 2002. Identification and expression of mouse Langerin (CD207) in dendritic cells. Int. Immunol. 14:433–444 10.1093/intimm/14.5.433
    1. Tsoumakidou M., Tzanakis N., Papadaki H.A., Koutala H., Siafakas N.M. 2006. Isolation of myeloid and plasmacytoid dendritic cells from human bronchoalveolar lavage fluid. Immunol. Cell Biol. 84:267–273 10.1111/j.1440-1711.2006.01428.x
    1. Velásquez-Lopera M.M., Correa L.A., García L.F. 2008. Human spleen contains different subsets of dendritic cells and regulatory T lymphocytes. Clin. Exp. Immunol. 154:107–114 10.1111/j.1365-2249.2008.03734.x
    1. Villadangos J.A., Schnorrer P. 2007. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol. 7:543–555 10.1038/nri2103
    1. Vremec D., Zorbas M., Scollay R., Saunders D.J., Ardavin C.F., Wu L., Shortman K. 1992. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J. Exp. Med. 176:47–58 10.1084/jem.176.1.47
    1. Witmer-Pack M.D., Swiggard W.J., Mirza A., Inaba K., Steinman R.M. 1995. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. II. Expression in situ in lymphoid and nonlymphoid tissues. Cell. Immunol. 163:157–162 10.1006/cimm.1995.1110
    1. Yamazaki S., Dudziak D., Heidkamp G.F., Fiorese C., Bonito A.J., Inaba K., Nussenzweig M.C., Steinman R.M. 2008. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J. Immunol. 181:6923–6933

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit